Hali­a's $30M Se­ries C; Windtree as­sess­es 's­trate­gic' op­tions; LifeArc, Gates in­vest in Africa ac­cel­er­a­tor

Plus, news about Cor­bus and Astel­las:

Halia Ther­a­peu­tics rais­es $30M Se­ries C: The com­pa­ny, which is de­vel­op­ing small mol­e­cules for in­flam­ma­to­ry dis­eases, plans to use the fund­ing to progress its lead as­set through Phase II tri­als. HT-6184 tar­gets the NLP3 in­flam­ma­some.

Windtree Ther­a­peu­tics to con­sid­er ‘strate­gic al­ter­na­tives’: The biotech last week said Deer­field Man­age­ment had ter­mi­nat­ed rights to a deal it made with Windtree back in 2017. The com­pa­ny is now con­sid­er­ing li­cens­ing deals, M&A or a sale.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER